drug_type
RELEVANT_DRUG
intervention_type
Radiopharmaceutical (PSMA-targeted radioligand therapy)
drug_description
PSMA-targeted radioligand therapy; a small-molecule PSMA ligand chelated to beta-emitter Lu-177 that binds PSMA, is internalized, and delivers beta radiation causing DNA double-strand breaks in tumor cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Pluvicto
drug_category
RADIOPEPTIDE CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
Small-molecule PSMA ligand chelated to lutetium‑177 binds PSMA on prostate cancer cells, is internalized, and emits β‑particles that cause DNA double‑strand breaks (with cross‑fire to nearby cells), leading to tumor cell death.
drug_name
Lutetium Lu 177 vipivotide tetraxetan (Pluvicto)
nct_id_drug_ref
NCT05682443